Is Amphastar Pharmaceuticals, Inc. (AMPH) a Buy, Sell, or Hold?
NASDAQ : AMPH
Amphastar Pharmaceuticals, Inc.
$19.745 USD
-$0.12 (-0.58%)
- Volume
- 331.5K
- Average Volume
- 614.76K
- Market Capitalization
- $870.61M
- P/E Ratio
- 11.55
- Dividend Yield
- 0.00%
- Price Target
- $20.50
- Year High
- $31.26
- Year Low
- $16.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.85
Company Overview
NASDAQ
Yongfeng Zhang
Drug Manufacturers - Specialty & Generic
Healthcare
AMPH
1976
US
USD
Liquidity Metrics
0.89
3.85
2.82
1.04
0.00
Sales & Valuation
$719.89M
1.21
1.16
6.44
2.98
Profitability
$2.03
$98.09M
11.00%
14.27%
10.23%
4.81%
P/E Metrics
11.55
-0.28
-0.28
Analyst Price Target & Rating
$20.50
$22.00
$19.00
4/5
12 Analysts
-3.68%
Poll Results
About Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low mol ... ecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
New Strong Sell Stocks for June 23rd
2026-06-23 06:16:05
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
2026-06-10 19:09:32
Amphastar Pharmaceuticals NASDAQ: AMPH is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors at the East Coast IDEAS Conference.
2026-06-08 08:19:00
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
2026-06-04 00:02:26
Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
2026-05-27 06:00:00
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
2026-05-14 02:06:01
Amphastar Pharmaceuticals NASDAQ: AMPH executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.
2026-05-13 20:50:46
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
2026-05-08 06:41:16
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Amphastar Pharmaceuticals, Inc. (AMPH) stock price?
-
Amphastar Pharmaceuticals, Inc.(NASDAQ:AMPH) stock price is $19.745 in the last trading session. During the trading session, AMPH stock reached the peak price of $31.26 while $16.65 was the lowest point it dropped to. The percentage change in AMPH stock occurred in the recent session was --0.58% while the dollar amount for the price change in AMPH stock was -$0.12.
-
AMPH's industry and sector of operation?
-
The NASDAQ listed AMPH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of AMPH?
-
Rong Zhou | Senior EVice President of Production & EVP of Scientific Affairs
William J. Peters | Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director
Jacob Liawatidewi | Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
Ziping Luo | Chairman of the Board, Chief Scientist & Chief Operating Officer
Tony Marrs | Executive Vice President of Regulatory Affairs & Clinical Operations -
How many employees does AMPH have?
-
Number of AMPH employees currently stands at 1976. AMPH operates from 11570 6th Street, Rancho Cucamonga, CA 91730, US.
-
Link for AMPH official website?
-
Official Website of AMPH is: https://www.amphastar.com
-
How do I contact AMPH?
-
AMPH could be contacted at phone #909 980 9484 and can also be accessed through its website. AMPH operates from 11570 6th Street, Rancho Cucamonga, CA 91730, US.
-
How many shares of AMPH are traded daily?
-
The average number of AMPH shares traded daily for last 3 months was 614.76K.
-
What is the market cap of AMPH currently?
-
The market value of AMPH currently stands at $870.61M with its latest stock price at $19.745